In 1QFY2024, IHH recorded its highest ever quarterly revenue at RM6 billion, up 16% y-o-y, while ebitda grew 19% y-o-y to RM1.4 billion. This is attributed to sustained patient volume as well as the take of more acute, complex cases.
IHH Healthcare has reported a patmi of RM768 million ($220 million) in 1QFY2024, down 45% y-o-y due to the absence of one-off gains.
The same period last year saw one-off gains of RM862 million from the sale of International Medical University. Excluding exceptional items, patmi was up 22%.
